What does SH stand for?

In this collection of 11 articles, contributors describe their work in PTKs in such areas as using PTKs as targets for cancer and other indications, targeting Src homology 2 domains in drug discovery, using P12-kinase inhibition as a target for therapeutic intervention, using an activated FLT3 receptor tyrosine kinase as a therapeutic target in leukemia and JAK kinases in leukemia, lymphomas and multiple myeloma, applying platelet-derived growth factor, using a targeted therapy for myelogenous leukemia, testing signal transduction inhibitors in animal models of cancer, and using phosphoproteomics in drug discovery and development.

Structure-based design of an osteoclast-selective, non-peptide Src homology 2 inhibitor with in vivo antiresorptive activity," highlights one of the candidate compounds in ARIAD's osteoporosis drug discovery program.